Cargando…

Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis

This study comprehensively investigated clinical outcomes associated with renin angiotensin system inhibitor-based dual antihypertensive regimens in non-dialysis chronic kidney disease (CKD) patients. Keyword searches of databases were performed per PRISMA-NMA guidelines. Frequentist network meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Miseung, Choi, Chang-Young, Choi, Yeo Jin, Rhie, Sandy Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082011/ https://www.ncbi.nlm.nih.gov/pubmed/37029191 http://dx.doi.org/10.1038/s41598-023-32266-4

Ejemplares similares

Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease?
por: Miyazaki, Hiroki, et al.
Publicado: (2015)

The renin-angiotensin system and aging in the kidney
por: Yoon, Hye Eun, et al.
Publicado: (2014)

Do inhibitors of the renin–angiotensin system prevent chronic kidney disease?
por: Rayner, Brian
Publicado: (2010)

Management of renin-angiotensin-aldosterone inhibitors and other antihypertensives and their clinical effects on pre-anesthesia blood pressure
por: Balcı, Eda, et al.
Publicado: (2022)

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease
por: Komers, Radko, et al.
Publicado: (2016)

Effect of Discontinuation of Renin Angiotensin-System Inhibitors in Patients With Advanced Chronic Kidney Disease: A Meta-Analysis
por: Naveed, Husnain, et al.
Publicado: (2023)

Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes
por: Bezabih, Yihienew M., et al.
Publicado: (2021)

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
por: Singhania, Namrata, et al.
Publicado: (2020)

Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system
por: Viazzi, Francesca, et al.
Publicado: (2013)

Effects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney
por: Jang, In-Ae, et al.
Publicado: (2018)

Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis
por: Tang, Chen, et al.
Publicado: (2023)

STRUCTURAL CHARACTERISTICS AND ANTIHYPERTENSIVE EFFECTS OF ANGIOTENSIN-I-CONVERTING ENZYME INHIBITORY PEPTIDES IN THE RENIN-ANGIOTENSIN AND KALLIKREIN KININ SYSTEMS
por: Manoharan, Sivananthan, et al.
Publicado: (2017)

Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease
por: Feng, Yan-Huan, et al.
Publicado: (2016)

Retarding the progression of chronic kidney disease with renin angiotensin system blockade
por: Limesh, M., et al.
Publicado: (2012)

The Effect of Renin-angiotensin System Inhibitors on Kidney Allograft Survival: A Systematic Review and Meta-analysis
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
por: Ravid, Mordchai
Publicado: (2009)

Prevalence of aldosterone breakthrough in dogs receiving renin‐angiotensin system inhibitors for proteinuric chronic kidney disease
por: Ames, Marisa K., et al.
Publicado: (2022)

Renin-Angiotensin System - Considerations for Hypertension and Kidney
por: Yim, Hyung Eun, et al.
Publicado: (2008)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
por: Goel, Mishita, et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Ku, Elaine, et al.
Publicado: (2018)

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials
por: Makani, Harikrishna, et al.
Publicado: (2013)

Efficacy and safety of dual vs single renin–angiotensin–aldosterone system blockade in chronic kidney disease: An updated meta-analysis of randomized controlled trials
por: Zhao, Mingming, et al.
Publicado: (2021)

Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease
por: Hsu, Chien-Ning, et al.
Publicado: (2019)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
por: Cahova, Monika, et al.
Publicado: (2021)

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis
por: Wu, Hon-Yen, et al.
Publicado: (2013)

P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
por: Park, Sohyun, et al.
Publicado: (2021)

The role of renin angiotensin system inhibition in kidney repair
por: van der Meer, Irene M, et al.
Publicado: (2010)

Independent regulation of renin–angiotensin–aldosterone system in the kidney
por: Nishiyama, Akira, et al.
Publicado: (2018)

Chronic effects of lead on the renin-angiotensin system.
por: Vander, A J
Publicado: (1988)

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Han, Yu Na, et al.
Publicado: (2022)

Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation
por: Aoki, Taro, et al.
Publicado: (2020)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016)

Medication use, renin–angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease
por: Neumiller, Joshua J, et al.
Publicado: (2020)

Lab monitoring and acute care utilization during initiation of renin angiotensin aldosterone inhibitors or diuretics in chronic kidney disease
por: Garlo, Katherine G., et al.
Publicado: (2019)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
por: Sackin, Henry
Publicado: (2021)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis
por: Choi, Yeo Jin, et al.
Publicado: (2022)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_crgh8jq1pa9q09mr56tbau0hkp